Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04316039 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery

Name: Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery — clinical trial record (NCT04316039)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2/3

SponsorWest China Hospital

StartedApr 10, 2018

View on ClinicalTrials.gov ↗

Record status

This record was last updated March 20, 2020 (before its estimated April 10, 2023 completion). Its status may not reflect the trial's current state.

Record History

Minor Mar 19, 2020 Study First Submitted

West China Hospital

264 trials monitored

See 13 trials at risk

Glioma

1,251 trials monitored

See 88 trials at risk

It has been reported that radiation therapy followed by PCV chemotherapy (procarbazine, lomustine and vincristine) could improve progression-free survival (PFS) and overall survival (OS) in patients with high-risk WHO grade 2 gliomas after surgery. However, procarbazine is not available in China. In clinical practice, Chinese doctors often use radiotherapy combined with temozolomide to treat these patients, though large-scale prospective studies are lacking. This trial aims to confirm whether RT combined with temozolomide can improve PFS and OS in patients with high-risk low-grade gliomas.

Trial Details

NCT Number	NCT04316039
Lead Sponsor	West China Hospital
Conditions (from sponsor)	Low-grade Glioma
Enrollment	250 participants
Start Date	Apr 10, 2018
Primary Completion	Apr 10, 2023 (estimated)
Study Completion	Dec 31, 2028 (estimated)
Updated on ClinicalTrials.gov	Mar 20, 2020